Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium

NCT03761901 · clinicaltrials.gov ↗

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: 1L treatment
DRUG: 2L Treatment
DRUG: 3L treatment

Sponsor

AstraZeneca